EC Approves TEPKINLY as First Bispecific Therapy for Follicular Lymphoma

Key Facts

In a move that strengthens innovation within the European oncology sector, the European Commission has granted marketing authorization for TEPKINLY (epcoritamab) for adult patients with relapsed or refractory follicular lymphoma. This drug marks the first bispecific-based, chemotherapy-free therapy approved for second-line treatment of this condition, administered in combination with lenalidomide and rituximab. The approval follows Phase 3 trial results demonstrating superior progression-free survival and high response rates compared to standard-of-care treatments.

This regulatory milestone intensifies competition in the hematologic oncology market, where giants like Roche and Novartis maintain significant presence. Per market data, Roche's Lunsumio previously secured approvals in similar indications, yet TEPKINLY’s specific combination therapy targets a critical second-line patient segment. Analysts suggest this expansion is a key growth driver for Genmab and its partner AbbVie in the European market, as healthcare providers increasingly pivot toward targeted therapies that mitigate the side effects associated with traditional chemotherapy.

Operationally, investors are monitoring the impact of this approval on upcoming financial results for the involved entities, though specific price levels for Genmab were unavailable at the time of this report. Looking ahead at the economic calendar, while there are no immediate biotech-specific catalysts, broader market sentiment may be influenced by upcoming Eurozone inflation data, including German and French CPI releases on June 30, 2026, which typically impact large-cap growth stocks in the region.